BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy

Nov 19, 2026

New Preclinical Findings Show TROP2 Levels May Help Predict REQORSA Treatment Response—and That Modifying TROP2 Expression May Increase Cancer Cell Sensitivity to Gene Therapy. Combined With the Roche Diagnostics Collaboration, Expanding TUSC2 Research and Advancing Clinical Programs, Genprex, Inc. (NAS DAQ: GNPX) Is Building Significant Momentum Across Its Innovative Biotechnology Platform.

AUSTIN, Texas - Nov. 19, 2026 - PRLog -- Genprex, Inc. (N A S D A Q: GNPX) $GNPX is bringing another exciting development to its growing gene therapy story with today's November 19 announcement of new preclinical data identifying TROP2 as a potential predictive biomarker for its lead investigational therapy, REQORSA® (quaratusugene ozeplasmid). Presented at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, the research offers important new insights into how TROP2 expression may influence the response of non-small cell lung cancer (NSCLC) to REQORSA.

What makes today's announcement especially interesting is that researchers are investigating more than simply whether TROP2 can identify patients likely to respond. The new findings also suggest that changing TROP2 expression may influence how cancer cells respond to TUSC2 gene therapy, potentially opening another avenue for improving treatment sensitivity.

For Genprex investors, this represents an important addition to an increasingly sophisticated precision-oncology strategy. The company is working to combine its innovative gene therapy platform with biomarker research that could help researchers better understand treatment response and identify patients who may benefit most.

Today's Big News: TROP2 Research Reveals Another Potential Advantage for REQORSA

The November 19 announcement highlights findings from research titled "TROP2 Predicts Response to TUSC2 Gene Therapy and Its Modulation Sensitizes Non-Small Cell Lung Cancer to Treatment."

Researchers evaluated multiple NSCLC cell lines and patient-derived organoid models to investigate the relationship between TROP2 expression and response to TUSC2 gene delivery.

The findings were particularly noteworthy:
  • Approximately 50% of the 10 NSCLC cell lines evaluated demonstrated primary resistance to TUSC2 gene delivery.
  • Approximately 50% of the 12 patient-derived organoid models also demonstrated primary resistance.
  • Low TROP2 protein expression was consistently associated with primary resistance across multiple preclinical models.
  • Analysis of pretreatment tumor biopsies from patients enrolled in a TUSC2 gene therapy clinical trial provided additional supporting evidence.

Perhaps the most intriguing aspect involved experiments examining whether changing TROP2 expression could influence treatment sensitivity.

Researchers introduced TROP2 into TROP2-low NSCLC cancer cells, including H460 and H1299 models. This significantly increased TUSC2-induced apoptosis, bringing the response to levels similar to cells naturally expressing higher TROP2.

This is an important scientific observation because it suggests TROP2 may have a role beyond simply identifying tumors that respond differently. Modifying its expression could potentially become another research strategy for enhancing REQORSA treatment.

The company believes these findings could help inform future patient-selection strategies and additional research into improving treatment response.

Roche Diagnostics Collaboration: A Powerful Addition to Genprex's Strategy

One of Genprex's most important strategic developments remains its collaboration with Roche Diagnostics, announced August 3.

The collaboration focuses on validating biomarker assays for non-small cell lung cancer, with particular attention to TROP2 and PTEN.

Roche brings extensive diagnostic expertise to the relationship, while Genprex contributes its developing REQORSA gene therapy platform and growing body of clinical and preclinical research.

The objective is to develop a more refined approach to identifying patients who may be more likely to benefit from REQORSA.

Previous clinical research suggested that higher TROP2 expression and lower PTEN expression were associated with longer progression-free survival in certain NSCLC patient groups.

Today's new findings add another important scientific component to this collaboration by providing additional evidence supporting the investigation of TROP2 as a potential predictive biomarker.

Genprex anticipated completing the Roche-related assay validation studies around the end of 2026, with potential incorporation into its NSCLC clinical program following successful validation.

The combination of Roche's diagnostic capabilities and Genprex's gene therapy research could become an important part of the company's precision-medicine strategy.

REQORSA: Advancing an Innovative Approach to Lung Cancer

At the center of Genprex's oncology platform is REQORSA, also known as quaratusugene ozeplasmid.

The investigational therapy is designed to deliver the TUSC2 tumor-suppressor gene into cancer cells using Genprex's proprietary ONCOPREX Delivery System, which utilizes lipid-based nanoparticles.

TUSC2 expression is reduced or absent in more than 80% of NSCLC cases and nearly all small cell lung cancers, making it an important target for investigation.

REQORSA is designed to restore tumor-suppressor activity and influence multiple biological pathways involved in cancer progression, including MAPK and mTOR signaling, cell-cycle regulation and programmed cancer-cell death.

Genprex is advancing two important clinical initiatives:

Acclaim-1: Evaluating REQORSA in combination with AstraZeneca's Tagrisso in patients with advanced NSCLC carrying specific EGFR mutations.

Acclaim-3: Evaluating REQORSA in an extensive-stage small cell lung cancer treatment strategy.

Both programs have received FDA Fast Track designation, while the small cell lung cancer program has also received Orphan Drug Designation.

New TUSC2 Research Expands the Scientific Story

Genprex has also been generating interest through its sponsored research collaboration with Meharry Medical College.

Recent research has examined TUSC2's role in cellular resilience, mitochondrial function and biological processes associated with aging.

On November 5, the company highlighted patient-derived research involving blood samples from 11 lung cancer patients receiving REQORSA. Researchers identified changes in gene-expression patterns associated with mitochondrial adaptation, autophagy, cellular maintenance and protein quality control.

These findings add another dimension to the understanding of TUSC2's biological activity in humans and complement the company's broader scientific investigation.

Diabetes Gene Therapy Adds Another Development Opportunity

Beyond oncology, Genprex is pursuing an additional opportunity through its diabetes gene therapy program.

The approach uses AAV technology to deliver Pdx1 and MafA genes to the pancreas, with the objective of restoring insulin-producing cell function.

Preclinical studies have produced encouraging findings in Type 1 and Type 2 diabetes models, including improvements in glucose control and insulin-related measures.

In August, Genprex announced the selection of a U.S.-based contract development and manufacturing organization to begin manufacturing scale-up for its diabetes gene therapy candidate.

This provides another important development program as the company works toward future clinical research.

The Road Ahead: Important Catalysts for GNPX Investors

Genprex has several important developments to watch as 2026 progresses:
  • Continued investigation of TROP2 as a potential predictive biomarker for REQORSA.
  • Further research into whether TROP2 modulation can enhance treatment sensitivity.
  • Anticipated completion of Roche Diagnostics biomarker assay validation.
  • Continued advancement of the Acclaim-1 and Acclaim-3 clinical programs.
  • Additional TUSC2 research and diabetes gene therapy development.

Genprex Is Building an Intriguing Precision Gene Therapy Platform

Today's November 19 announcement adds another important milestone to Genprex's developing story. The TROP2 findings are particularly interesting because they suggest two potential opportunities: identifying patients more likely to respond to REQORSA and investigating whether changing TROP2 expression could increase treatment sensitivity.

Combined with the Roche Diagnostics collaboration, these findings strengthen the scientific foundation behind Genprex's precision-oncology ambitions.

The company's continued TUSC2 research, advancing lung cancer clinical programs and separate diabetes gene therapy initiative provide multiple areas of development to follow.

For investors watching emerging biotechnology opportunities, Genprex is building an increasingly compelling story around innovative gene therapy, strategic diagnostic collaboration and personalized cancer treatment. With today's new TROP2 findings adding another exciting dimension to REQORSA, GNPX has important scientific milestones ahead as it works to translate its research into meaningful clinical progress.

For more information on $GNPX visit: www.genprex.com and https://compasslivemedia.com/gnpx/

Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: [email protected]
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website

Contact
CorporateAds
***@gmail.com

Photos: (Click photo to enlarge)




Source: CorporateAds

Read Full Story - BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy | More news from this source

Press release distribution by PRLog

More News

Alcaraz reaches ATP Finals last four
Nov 19, 2026

Alcaraz reaches ATP Finals last four

TURIN, Italy — Carlos Alcaraz reached the last four of the ATP Finals on Wednesday (Thursday in Manila) thanks to Frances Tiafoe after the Spaniard had earlier brushed aside world No. 5 Daniil Medvedev, 6-2, 6-4. American Tiafoe beat Italian Flavio Cobolli, 7-6 (8/6), 6-0, with his first set guaranteeing Alcaraz’s spot in the next round. Tiafoe kept his hopes of a semifinal spot alive in his maiden Finals appearance and faces Medvedev in his last group-stage match on Friday. Seven-time Grand Slam champion Alcaraz needed just over 70 minutes to beat the Russian in Turin. “A little bit of problems, you know, physically, in the match,” Alcaraz said on-court after receiving some treatment in the second set. “But I think everybody could see that I was able to still play good tennis, I could still move well.” By winning in straight sets, the 23-year-old will secure his spot in the semifinals if Frances Tiafoe defeats Flavio Cobolli later or if the Italian beats the American in three sets. Alcaraz has never won the season-ending Finals, finishing runner-up last year to Jannik Sinner. But with Sinner injured and the Spaniard entering this season’s edition on the back of a nine-match winning streak that earned him indoor titles in Vienna and at the Paris Masters, Alcaraz is considered the favorite to lift the trophy this year. Since returning in August from a wrist injury that kept him off the tour for four months and prevented him from defending his French Open title, Alcaraz has won three of the five tournaments he has entered. After easing past Tiafoe in his opener in Turin, 6-2, 6-2, the third seed carried that ominous form into the first set against 2020 Finals winner Medvedev. Alcaraz broke the Russian in successive games midway through the first frame to claim the opener. He continued by breaking Medvedev in the very first game of the second set and proceeded to serve out, despite a brief stoppage to have his left thigh taped up. “I didn’t want to force myself to the limit physically. I was a break-up at that time. And I just tried to keep up my serve ... play chill, smoothly, relaxed and just happy about it,” Alcaraz said. “So, I’m going to look at it with my team and I will see.” Medvedev, 30, is still in with a chance of advancing after winning his opening match against Cobolli in straight sets. World No. 1 Alexander Zverev is the man to beat in the John McEnroe Group and became the first player to book his spot in the semifinals after beating Ben Shelton on Tuesday.

Sixers rally to thwart Magic
Nov 19, 2026

Sixers rally to thwart Magic

LOS ANGELES — The Philadelphia 76ers produced another double-digit comeback to defeat the Orlando Magic, 121-116, and extend their lead at the top of the NBA Eastern Conference on Wednesday (Thursday in Manila). ed a decisive 13-point fourth-quarter burst in a 24-point performance as Philadelphia improved to 13-3. LeBron James also weighed in with 22 points after the Sixers recovered from a 17-point first-quarter deficit to claw their way back and extend their winning streak to four games. It was the sixth time this season the Sixers have come back to win after trailing by 10 points or more. Philadelphia coach Nick Nurse admitted he had feared the worst after watching a rampant Orlando score 40 points in the first quarter. “They were just flying around at 100 miles an hour and we weren’t right,” Nurse said. “They were really putting it on us. We had to try to change a few things and change the rhythm of the game. “Sometimes that works and sometimes it doesn’t.” Philadelphia trailed until midway through the fourth quarter, taking the lead with just over five minutes remaining via a Jabari Walker three-pointer. “We did a very nice job tonight of our execution offensively down the stretch,” Nurse said. “We worked on some stuff this morning that we hadn’t used before, and ran all that stuff very well and very calmly and with composure.” The Miami Heat continued their march up the standings with a sixth straight win in a 137-130 defeat of the Milwaukee Bucks. Giannis Antetokounmpo finished with 27 points, 13 rebounds and nine assists against his former club while Bam Adebayo added 26 points. Davion Mitchell rattled in six three-pointers in a 24-point gem. Miami, who improved to 9-6, were always in control in a wire-to-wire victory that saw them lead by as many as 30 points in the fourth quarter. The Bucks have now lost 11 straight and remain at the foot of the table. AFP In Cleveland, the Memphis Grizzlies improved to 11-4 with a 124-121 defeat of the Cavaliers in a game that saw the lead change hands 22 times. Cam Spencer led Memphis with 26 points as Donovan Mitchell’s 34-point display for Cleveland ended in defeat.

Korda looking for big finish to a great year
Nov 19, 2026

Korda looking for big finish to a great year

NAPLES, Florida — Nelly Korda arrived at the LPGA Tour’s season finale with the potential for history in front of her. A victory in the CME Group Tour Championship puts her in the LPGA Hall of Fame at age 28 and moves her past Annika Sorenstam atop the tour’s career money list. That’s of little concern. Korda has spent much of her week looking back at what led to another stellar season and the one trophy — the US Women’s Open at Riviera — she desperately wanted. Reflections are not all positive. Imagine a video of all the great golf played around the world this year with each star player getting only one highlight. What would she choose? The high-risk wedge she played to a tuck pin when she won the first major of the year at The Chevron Championship? That 3-foot putt that lipped in on the 18th at Riviera for a one-shot victory? She chose a missed short putt, the occasional nemesis in her game. “I feel like as athletes, as golfers, we want to be such perfectionists that people don’t realize we make mistakes, and we miss what amateurs miss,” Korda said Wednesday. “Athletes should just be more vulnerable as human beings. Sometimes we are put under such a microscope where we can’t mistakes — whereas you can make mistakes and still rise to the occasion.” That’s what she considers the key to her year. She started the season by playing in the final group in six straight tournaments — three wins, three runner-up finishes. This followed a season in which she didn’t win at all, coming off seven wins in 2024. Korda was dressed to the nines Tuesday night at the awards banquet to accept LPGA player of the year, which she clinched with two tournaments left in the season. Through a few tears after hearing big sister Jessica narrate a video of her season — Korda hates crying in public — she preached a message of accepting mistakes instead of living up to a reputation of sheer greatness. “I was so tired of being afraid to make mistakes that it blocked me up even more,” she said at the banquet. “I told myself that I just don’t want to play golf that way. I don’t want to live life that way. I want to be able to breathe. So, I went into this year saying, ‘OK, I’ll figure it out.’ If I make a mistake, I’ll go into it with a mindset of I’ll just figure it out.” That she did. Now comes the final act at Tiburon Golf Club, a season finale for the top 60 players all with an equal chance at the $4 million prize, by far the largest in women’s golf. Anyone who wins is crowned the Race to CME Globe champion. The leading contenders are familiar faces — Haeran Ryu, who won two straight majors after Korda and Jeeno Thitikul, the defending champion at Tiburon who briefly overtook Korda at No. 1 in the world last year when the American was not winning. AP “I think it’s a course that you just need to go aggressive on it because like you don’t have anything to lose,” Thitikul said. “I think everyone who came here, we just came here for bonus. It’s the last event of the year. I feel like going for the pin is the only answer to be able to hoist the trophy.” Korda was in good spirits during the pro-am Wednesday, singing and dancing to music as she rode the cart on a resort course that requires a half-dozen cart rides between greens and tees. It was not built for walking. Her last victory was the US Women’s Open the first week in June. She has played only eight times since then, skipping the four-tournament swing through Asia again to recharge and reset. Dating to her big breakthrough in 2021, when she won her first major at Atlanta Athletic Club, reached No. 1 in the world for the first time and won Olympic gold in Japan, she has yet to win on the LPGA Tour from July until November. “Still trying to figure out that middle part of the year,” she said. She says it has nothing to do with a post-US Open letdown. It seems similar to Rory McIlroy, chasing a Masters green jacket for 17 years until finally winning — to complete the career Grand Slam — and then going five months before his next victory. “As for losing motivation or knowing one of the biggest wins I wanted in my career was checked off, that doesn’t mean I have less motivation,” Korda said. “It’s actually the opposite. I want to be in that position more and more.”

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.